Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lenz

Showing results (321-330 of 367) with videos related to

Pageof 37
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignanciesM L Tetef, T W Synold, W Chow, et al.
Journal of Applied Microbiology|February 1, 2011
An international trial of quantitative PCR for monitoring Legionella in artificial water systemsJ V Lee, S Lai, M Exner, et al.
The Pharmacogenomics Journal|January 11, 2012
Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapyA Pohl, A El-Khoueiry, D Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinomaLawrence P Leichman, Bryan H Goldman, Pierre O Bohanes, et al.
British Journal of Cancer|March 11, 2015
Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumoursA J Zurita, M Khajavi, H-K Wu, et al.
Pacing and Clinical Electrophysiology : PACE|February 16, 2021
Sinus rhythm heart rate increase after atrial fibrillation ablation is associated with lower risk of arrhythmia recurrenceAmmar M Killu, Chance M Witt, Alan M Sugrue, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trialsM D Berger, S Stintzing, V Heinemann, et al.
Cancer Chemotherapy and Pharmacology|January 9, 2015
A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridineEdward M Newman, Robert J Morgan, Shivaani Kummar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2010
A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapyW Zhang, T Winder, Y Ning, et al.
British Journal of Pharmacology|October 16, 2007
Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinaseR Kast, H Schirok, S Figueroa-Pérez, et al.
Pageof 37

Showing results (321-330 of 367) with videos related to

Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignanciesM L Tetef, T W Synold, W Chow, et al.
Journal of Applied Microbiology|February 1, 2011
An international trial of quantitative PCR for monitoring Legionella in artificial water systemsJ V Lee, S Lai, M Exner, et al.
The Pharmacogenomics Journal|January 11, 2012
Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapyA Pohl, A El-Khoueiry, D Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinomaLawrence P Leichman, Bryan H Goldman, Pierre O Bohanes, et al.
British Journal of Cancer|March 11, 2015
Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumoursA J Zurita, M Khajavi, H-K Wu, et al.
Pacing and Clinical Electrophysiology : PACE|February 16, 2021
Sinus rhythm heart rate increase after atrial fibrillation ablation is associated with lower risk of arrhythmia recurrenceAmmar M Killu, Chance M Witt, Alan M Sugrue, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trialsM D Berger, S Stintzing, V Heinemann, et al.
Cancer Chemotherapy and Pharmacology|January 9, 2015
A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridineEdward M Newman, Robert J Morgan, Shivaani Kummar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2010
A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapyW Zhang, T Winder, Y Ning, et al.
British Journal of Pharmacology|October 16, 2007
Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinaseR Kast, H Schirok, S Figueroa-Pérez, et al.
Pageof 37